In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Pharmaceutical Co. Ltd.

http://www.takeda.com

Latest From Takeda Pharmaceutical Co. Ltd.

What To Expect From India’s Proposed National Pharmaceutical Policy

An updated National Pharmaceutical Policy aimed at enhancing India’s self-reliance and global competitiveness is on the cards. A focus on private-public partnering and academia-industry linkages means much of its success will depend on the ability of various parties to deliver within the constraints they operate in

Policy Innovation

Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo

The Swiss firm reported that its oral bradykinin B2 receptor antagonist reduced monthly hereditary angioedema attacks by 84.5% compared with placebo, suggesting biologic-like efficacy with an oral drug.

Clinical Trials Rare Diseases

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

Japan Financing

Project Orbis 2023: FDA Approves Six New Cancer Drugs, But Partner Nations Lag Behind

Sixteen cancer therapies have been granted marketing authorizations or label variations in the US this year via the Project Orbis scheme. However, the majority of these are still under review by Orbis partners, which have also been outpaced by the non-Orbis EU.

BioPharmaceutical Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adaptate Biotherapeutics Ltd
    • Altos Therapeutics LLC
    • AR Scientific, Inc. (URL)
    • ARIAD Pharmaceuticals, Inc.
    • Bradley Pharmaceuticals, Inc
    • Cellerix SA
    • Cerevance, Envoy Therapeutics, Inc.
    • Chordia Therapeutics
    • ChromaJean, Inc.
    • GammaDelta Therapeutics
    • IDM Pharma
    • Intellikine, Inc.
    • Inviragen, Inc.
    • LigoCyte Pharmaceuticals, Inc.
    • Maverick Therapeutics, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Mutual Pharmaceutical Company, Inc. (URL)
    • Neutec
    • Nihon Pharmaceutical Co., Ltd
    • Nycomed Pharma AS
    • Pharmaceutical Holdings Corporation (URL)
    • PvP Biologics, Inc.
    • sanaplasma AG
    • Syrrx, Inc.
    • TAP Pharmaceutical Products, Inc.
    • Teva Takeda Pharma Ltd.
    • Shire Pharmaceuticals Group PLC (SHPG)
    • Teva Takeda Yakuhin Ltd.
    • TiGenix NV
    • URL Pharma, Inc. Advanced BioHealing, Inc. (renamed Shire Regenerative Medicine)
    • AesRX LLC
    • Baxalta Incorporated
    • BIKAM Pharmaceuticals Inc.
    • Chatham Therapeutics
    • Dyax Corp.
    • FerroKin BioSciences, Inc.
    • Fibrotech Therapeutics
    • Foresight Biotherapeutics Inc.
    • Gambro AB
    • Immuno-US
    • Jerini AG
    • Lotus Tissue Repair
    • Lumena Pharmaceuticals
    • Meritage Pharma, Inc.
    • Movetis NV
    • New Pervasis Therapeutics, Inc.
    • NPS Pharmaceuticals, Inc.
    • Premacure AB
    • Prism Pharmaceuticals, Inc.
    • River Pharmaceuticals
    • Roberts Pharmaceutical Corporation
    • SARcode Corporation
    • SuppreMol GmbH
    • Synovis Life Technologies, Inc.
    • Transkaryotic Therapies, Inc.
    • ViroPharma Inc.
UsernamePublicRestriction

Register